CDK1 and laryngeal carcinoma: Based on the above background, this study aims to investigate whether lncRNA FLJ20021 can affect cisplatin resistance in laryngeal cancer through PANoptosis and to explore how lncRNA FLJ20021 can participate in the regulation of cisplatin resistance in LC through the regulation of CDK1-mediated PANoptosis to provide promising therapeutic targets for the treatment of laryngeal cancer.